Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Post by HighSkies2019on Sep 16, 2021 12:46am
219 Views
Post# 33867149

Letter !!!

Letter !!!Can't wait to see what the letter entails ...it could be the deciding factor for many ...anything is possible ...maybe an offer on buy back of shares ...buyout or lisence deal ...not unless someone knows for certain like the GVHD program ...as someone that has been part of acquisitions and contracts thought there was a possible chance ... but I have been told its a done deal ...I guess maybe the letter will tell us why the transaction didn't happen with the GVHD...anyways it normally takes 6 to 8 wks to complete first transaction on a PP. that's without covid hold ups..we are 4 wks in as of this wk ... so until we hear of the letter from Bob its looking like Oct or later b4 clinical trials start ... guess we just have to wait and see ...glta
<< Previous
Bullboard Posts
Next >>